The phase 3 portion of the trial will test safety and efficacy of a single intravenous infusion ... is based on a cocktail of two antibodies that neutralise the virus. Shares in Regeneron were ...

Regeneron has said it has begun clinical trials of its antibody cocktail therapy for COVID-19, as pharma companies continue their search for treatments as the pandemic continues to cause havoc ...

One of those is monoclonal antibodies ... It does not require an infusion center. It appeared that when given that way, the cocktail was very effective, and so we are talking with the FDA about ...

Monoclonal antibody ... with Regeneron’s combination of casirivimab and imdevimab — the treatment which the FDA OK’d for shots. Previously, clinical trials had only studied IV infusion ...

Here is what is currently known about the drugs Trump has been taking to combat his illness: One of the first reported treatments Trump received was an experimental cocktail of two monoclonal ...